James Crowley Highlights John DiPersio Immunotherapy Symposium on AML and CAR T
James Crowley, Professor of Medicine Emeritus at Brown University, shared a post on LinkedIn:
“The John F. DiPersio Immunotherapy Symposium took place on Wednesday March 27, 2024. Dr. DiPersio has played a key leadership role in the team-science work at Washington University that has defined the genetic and epigenetic factors that contribute to clonal evolution and relapse in AML. His group was the first to use whole genome sequencing to define clonal evolution at relapse resulting from the expansion of very small genetically defined AML subclones.
Recently, this group showed that epigenetic downregulation of HLA Class II antigens on AML blasts is associated with immune escape, often leading to relapse after allogeneic transplantation.
Together, these studies have changed our understanding of AML relapse after chemotherapy and/or transplantation.
The symposium honors John DiPersio’s contributions to the understanding of the pathogenesis of and development of new treatments for hematopoietic malignancies.
The symposium featured presentations by three leaders in the field of cancer immunotherapy.
Dr. Stanley Riddell (Fred Hutchinson Cancer Research Center) discussed strategies to optimize the use of T cell immunotherapy based. Dr. Jedd Wolchok (Weill Cornell) discussed recent work to augment immune checkpoint blockade for the treatment of melanoma.
Finally, Dr. Carl June (University of Pennsylvania) presented his ground-breaking research on enhancing CAR T cell therapies.
Videos of these three presentations as well as the Dr. DiPersio’s speech are available here.”
More posts featuring James Crowley on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023